登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
ClinicalTrials.gov 上登记的一项特发性肺纤维化开放试验。牵头方不是本站收录的医院;本站收录的 45 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 45
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心内蒙古医科大学附属医院Affiliated Hospital of Inner Mongolia Medical University呼和浩特医院页面
- 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
- 研究中心安徽省胸科医院Anhui Chest Hospital合肥医院页面
- 研究中心首都医科大学附属北京朝阳医院Beijing Chao-Yang Hospital北京医院页面
- 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
- 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
- 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
- 研究中心宁波大学附属第一医院First Affiliated Hospital of Ningbo University宁波医院页面
- 研究中心山东第一医科大学第一附属医院(山东省千佛山医院)First Affiliated Hospital of Shandong First Medical University济南医院页面
- 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心西安医学院第一附属医院First Affiliated Hospital of Xi'an Medical College西安医院页面
- 研究中心新疆医科大学第一附属医院First Affiliated Hospital of Xinjiang Medical University乌鲁木齐医院页面
- 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
- 研究中心昆明市第一人民医院First People Hospital昆明医院页面
- 研究中心福州大学附属省立医院Fuzhou University Affiliated Provincial Hospital福州医院页面
- 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面
- 研究中心杭州市第一人民医院Hangzhou First People's Hospital杭州医院页面
- 研究中心河北医科大学第三医院Hebei Medical University Third Hospital石家庄医院页面
- 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
- 研究中心江西省人民医院Jiangxi Provincial People' Hospital南昌医院页面
- 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
- 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
- 研究中心南阳市第一人民医院Nanyang First People's Hospital南阳医院页面
- 研究中心宁波市医疗中心李惠利医院Ningbo Medical Center Lihuili Hospital宁波医院页面
- 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
- 研究中心山东大学齐鲁医院Qilu Hospital of Shandong University济南医院页面
- 研究中心武汉大学人民医院Renmin Hospital of Wuhan University武汉医院页面
- 研究中心西安交通大学第二附属医院Second Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心厦门市第二医院Second Affiliated Hospital of Xiamen Medical College厦门医院页面
- 研究中心河北医科大学第二医院Second Hospital of Hebei Medical University石家庄医院页面
- 研究中心吉林大学第二医院Second Hospital of Jilin University长春医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital, Tongji University上海医院页面
- 研究中心山西白求恩医院Shanxi Bethune Hospital太原医院页面
- 研究中心中国医科大学附属盛京医院Shengjing Hospital of China Medical University沈阳医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心天津市胸科医院Tianjin Chest Hospital天津医院页面
- 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心四川大学华西医院West China Hospital成都医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心宜昌市中心人民医院Yichang Central People's Hospital宜昌医院页面
- 研究中心版权所有 运城市中心医院Yuncheng Central HospitalYuncheng医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07687459,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
40 岁 至 未注明;性别:不限
登记记录的入选字段
Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
入选标准第 3 条
not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
入选标准第 11 条
Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
入选标准第 12 条
Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
排除标准第 16 条
Patients (female) who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study (for female)
排除标准第 25 条
DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
入选标准第 8 条
Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.0 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
排除标准第 10 条
Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
排除标准第 17 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07687459,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation. Patients aged ≥40 years at time of signing the ICF. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit. UIP or probable UIP with fibrosis extent >10% at HRCT. Meet all the following criteria during the screening period: FVC ≥45% predicted of normal FEV1/FVC ≥0.7 DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal. Background antifibrotic therapies are allowed, patients may be either: on monotherapy with nintedanib or pirfenidone must have been on a stable therapy for at least 12 weeks prior to randomization. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy. Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.排除标准:Exclusion Criteria:
Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone). Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed. Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities. Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period. Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis. Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period. Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), and patients with non-alcoholic steatohepatitis. Patients with hyperbilirubinemia or Gilbert's syndrome. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis. Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.0 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening. Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening. Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1). Patient with a history of lung volume reduction surgery or lung transplant. Current smoker and/or cotinine (smoking) test positive. History of drug abuse, drug use, or alcohol abuse within the past 3 months. Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit. Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications. Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor. Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period. Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers Medications associated with substantial risk for prolongation of corrected QT interval. Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1. Patients (female) who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study (for female) Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors. Any condition that would interfere with the interpretation of study assessments or impair study participation. Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
引自 ClinicalTrials.gov, NCT07687459, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07687459,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。